Summary of minutes of EUCAST Steering Committee Meeting
Stockholm, Sweden, 11-12 July 2011

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Clinical Data Co-ordinator Spain
Prof Luc Dubreuil LD CA-SFM France
Dr Christian Giske CG SRGA Sweden
Dr Marina Ivanova MI EUCAST Estonia
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Dr Martin Steinbakk MS NWGA Norway

Apologies
Dr Petra Apfalter PA EUCAST Austria
Prof Claude-James Soussy CS CA-SFM France

Present on 11 July 2011
Dr Marc Struelens MSt ECDC Sweden

1 Chairman’s welcome Prof Arne Rodloff has resigned from the Steering Committee. A National Antimicrobial Susceptibility Committee has been formed in Australia and their formal application to join the EUCAST General Committee has been approved by ESCMID.

2 Minutes of meeting of 10-11 May 2011 The minutes were accepted as a correct record.

3 Matters arising from minutes of 10-11 May 2011 (items not covered by agenda)
A paper for CMI explaining ECOFFs is being prepared.

Policy on breakpoints for agent-organisms for which there is no license is being discussed.

There are current discussions on definition of susceptibility testing methods for gonococci.

Screening methods for detection of β-lactam resistance in H. influenzae are being investigated.

A questionnaire to send to General Committee representatives asking for common dose, maximum dose and available formulations used in their country is to be produced.

Breakpoint changes for M. catarrhalis have been published on the website and will be incorporated into the next version of the breakpoint tables.

Revised statutes have been published on the EUCAST website.

A guidance document on direct antimicrobial susceptibility testing is being drafted.

The reliability of ciprofloxacin disk diffusion testing of Salmonella spp. is to be reviewed.

Significant breakpoints splitting the wild type will be dealt with as soon as possible.

4 New agents EMA has recommended marketing authorisation for telavancin with limited application. Two new agents for TB are likely to be submitted within the next year. There have been preliminary discussions on a new ketolide agent.

5 Status of EUCAST rationale documents To be discussed at the next meeting. Each year when breakpoint tables are updated the rationale documents will be checked and updated if required.

6 Breakpoint issues Proposed breakpoints for levofoxacin and moxifloxacin with viridans group streptococci and for cefixime with N. gonorrhoeae will be released on general consultation. Pk/Pd breakpoints for colistin are unclear and further discussion will take place. If there is evidence relating MIC to outcome for Enterobacteriaceae and oral cephalosporins EUCAST would be happy to review breakpoints. ECOFF-based breakpoints for topical agents are being discussed. The
susceptible linezolid breakpoint for *S. pneumoniae* in the current EUCAST tables is incorrectly listed as $S \leq 4$ mg/L rather than $\leq 2$ mg/L: it will be corrected in the next version of the tables. Problems with the nitrofurantoin breakpoint splitting the *E. faecium* wild type and vancomycin breakpoints for coagulase-negative staphylococci were discussed.

### 7 Expert rules subcommittee
Version 2 should be published by CMI within a few weeks. The subcommittee has now been disbanded.

### 8 Antifungal susceptibility testing subcommittee
No new information.

### 9 Anaerobe subcommittee
The subcommittee will be disbanded and work continued in collaboration with the ESCMID study group.

### 10 Organisms without EUCAST breakpoints
*N. meningitidis* discussions with IBD-Labnet continue. *H. pylori* breakpoints and *C. difficile* ECOFFs have been released. For *Campylobacter* spp a multi-centre project is in progress. For *Legionella* spp work with the European study group is proposed. Results from the multi-centre *Listeria* spp project were discussed. Proposals for ECOFFs for *P. multocida* were reviewed. A multi-centre project on *Corynebacterium* spp, *Stenotrophomonas maltophilia*, *Vibrio cholera*, *Aerococcus* spp., and *Actinobaculum* spp.

### 11 ESCMID
EUCAST sessions have been proposed for ECCMID 2012. There will be a combined EUCAST/ESGARS/EPASG Postgraduate Educational Course in Madrid in September 2012.

### 12 EMA
A consultation document on development of paediatric drugs has been released.

### 13 CLSI
A report was given on the meeting in Boston, June 2011.

### 14 ECDC
A document on case definitions for antimicrobial resistance has been released.

### 15 Implementation of EUCAST breakpoints
There have been no very recent changes in national status. Manufacturers’ readiness for EUCAST breakpoints and methods was reviewed and slow progress with some automated systems noted.

### 16 Viridans group streptococci
Agreed to standardise terminology to "viridians group streptococci".

### 17 Website
Updates have been introduced to presentation of MIC and zone diameter distributions.

### 18 Co-amoxiclav breakpoints and susceptibility testing
Deferred to next meeting.

### 19 Screening for β-lactam resistance in viridans group streptococci
A study is in progress to assess use of the 1 unit (0.6µg) penicillin disk to screen for β-lactam resistance.

### 20 Web-based information project
Collaboration on a proposed project was discussed.

### 21 Paper on Pk/Pd in breakpoint setting
The paper is close to a final draft.

### 22 New cephalosporin
Proposed breakpoints were discussed.

### 23 Any other business
None.

### 24 Next meetings
- 26-27 September 2011, Zurich, Switzerland.
- 21-22 November 2011, Brussels, Belgium
- 30-31 January 2012, Lille, France
- 3-4 April 2012, London, UK
- 9-10 July 2012, Stockholm, Sweden
- 24-25 September 2012, Madrid, Spain

Ratified summary of minutes of meeting 11-12 July 2011. Prepared by DB, GK and RC